CRIS Current Research Information System

RASCHI, EMANUEL
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 11.168
NA - Nord America 9.972
EU - Europa 7.046
SA - Sud America 680
AF - Africa 624
OC - Oceania 43
Continente sconosciuto - Info sul continente non disponibili 6
Totale 29.539
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.790
SG - Singapore 3.049
CN - Cina 2.743
VN - Vietnam 2.667
IT - Italia 1.734
GB - Regno Unito 1.486
HK - Hong Kong 1.014
DE - Germania 868
SE - Svezia 556
BR - Brasile 508
IN - India 507
FR - Francia 453
RU - Federazione Russa 347
NL - Olanda 309
KR - Corea 298
FI - Finlandia 260
IE - Irlanda 236
JP - Giappone 229
CI - Costa d'Avorio 203
TG - Togo 160
UA - Ucraina 159
ZA - Sudafrica 135
CA - Canada 114
ID - Indonesia 87
AT - Austria 81
EE - Estonia 81
BG - Bulgaria 79
PH - Filippine 71
AR - Argentina 69
TR - Turchia 65
JO - Giordania 61
ES - Italia 59
TH - Thailandia 59
CH - Svizzera 57
BD - Bangladesh 56
PL - Polonia 56
BE - Belgio 53
MX - Messico 45
TW - Taiwan 41
IQ - Iraq 40
AU - Australia 34
PT - Portogallo 34
SA - Arabia Saudita 33
EC - Ecuador 30
UZ - Uzbekistan 29
PK - Pakistan 27
NG - Nigeria 24
SC - Seychelles 24
HR - Croazia 22
CL - Cile 20
CO - Colombia 20
GR - Grecia 20
LT - Lituania 18
MY - Malesia 18
KE - Kenya 15
IL - Israele 14
EG - Egitto 13
CZ - Repubblica Ceca 12
TN - Tunisia 11
MA - Marocco 10
RO - Romania 10
VE - Venezuela 10
DK - Danimarca 9
DZ - Algeria 9
NZ - Nuova Zelanda 9
PY - Paraguay 9
IR - Iran 8
PE - Perù 8
LB - Libano 7
SK - Slovacchia (Repubblica Slovacca) 7
BA - Bosnia-Erzegovina 6
HU - Ungheria 6
KZ - Kazakistan 6
NP - Nepal 6
AE - Emirati Arabi Uniti 5
GH - Ghana 5
OM - Oman 5
SI - Slovenia 5
UY - Uruguay 5
ET - Etiopia 4
HN - Honduras 4
MT - Malta 4
RS - Serbia 4
SM - San Marino 4
AZ - Azerbaigian 3
CY - Cipro 3
DO - Repubblica Dominicana 3
EU - Europa 3
JM - Giamaica 3
NI - Nicaragua 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AM - Armenia 2
DM - Dominica 2
KH - Cambogia 2
KW - Kuwait 2
LK - Sri Lanka 2
MD - Moldavia 2
NO - Norvegia 2
PR - Porto Rico 2
Totale 29.507
Salva come PNG Salva come JPEG
Città #
Singapore 2.101
Southend 1.209
Ashburn 1.026
Hong Kong 940
Fairfield 849
Hefei 660
Chandler 651
Ho Chi Minh City 631
Bologna 503
Hanoi 493
San Jose 488
Santa Clara 410
Dong Ket 391
Wilmington 389
Woodbridge 387
Seattle 370
Princeton 318
Beijing 313
Houston 310
Cambridge 298
Seoul 274
Ann Arbor 254
Boardman 248
Dublin 231
Los Angeles 222
Helsinki 218
Abidjan 203
Lauterbourg 191
Tokyo 172
Council Bluffs 168
Dallas 159
Lomé 159
Redmond 140
New York 110
Westminster 99
Milan 98
Berlin 97
Buffalo 90
Nanjing 88
London 84
The Dalles 83
Da Nang 80
Haiphong 80
Padova 80
Sofia 77
Frankfurt am Main 72
Redondo Beach 71
Rome 67
Saint Petersburg 66
Jinan 64
Turin 63
Bengaluru 62
Shanghai 61
Jacksonville 60
Amman 59
Florence 59
Munich 58
San Diego 57
Jakarta 56
São Paulo 56
Guangzhou 55
Falls Church 51
Shenyang 49
Vienna 49
Brussels 47
Bremen 46
Chicago 46
Toronto 43
Biên Hòa 42
Modena 42
Des Moines 41
Orem 41
Medford 39
Nuremberg 38
Amsterdam 37
Hebei 37
Bern 36
Hangzhou 36
Tianjin 35
Changsha 34
Nanchang 33
Paris 32
Warsaw 32
Boydton 31
Phoenix 31
Johannesburg 30
Zhengzhou 30
Bangkok 28
Shenzhen 28
Jiaxing 26
San Francisco 26
Falkenstein 25
Hải Dương 25
Montreal 25
Dearborn 24
Mülheim 24
Verona 24
Biella 23
Can Tho 22
Porto 22
Totale 18.758
Salva come PNG Salva come JPEG
Nome #
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. 487
ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance 483
ROCCA cohort study: Nationwide results on safety of Gam-COVID-Vac vaccine (Sputnik V) in the Republic of San Marino using active surveillance 349
Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems 337
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system 305
Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS) 295
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct 287
Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals 283
Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies 269
Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems 259
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System 256
Appropriateness of Proton Pump Inhibitor (PPI) prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy 255
hERG-related drug toxicity and models for predicting hERG liability and QT prolongation 252
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 245
Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database. 237
Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection 234
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System 233
Advancements in drug development for diarrhea-predominant irritable bowel syndrome 229
Pattern of drug use among preterm neonates: Results from an Italian neonatal intensive care unit 225
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. 220
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System 219
Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database 219
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 213
Antimicrobials and the Risk of Torsades de Pointes. The Contribution from Data Mining of the US FDA Adverse Event Reporting System 205
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry 205
Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure 203
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System 203
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System 201
Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis 195
Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres 195
Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey 193
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database 192
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System 191
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS 189
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: beyond bleeding complications 188
Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System 188
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones: A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database. 187
The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project 186
Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping 183
Drug-induced Kounis syndrome: A matter of pharmacovigilance 183
Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system 181
Clinically important drug-drug interactions in poly-treated elderly outpatients: A campaign to improve appropriateness in general practice 179
Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis 179
Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region 179
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors 178
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People 177
Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development 176
Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis 176
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study 174
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems 174
Pro-arrhythmic potential of oral antihistamines (H1): Combining adverse event reports with drug utilization data across Europe 173
Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing 172
Prevalence and determinants of long-term utilization of antidepressant drugs: A retrospective cohort study 172
Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction 171
QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus 169
The hERG K+ channel: target and antitarget strategies in drug development. 168
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE? 167
Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology 164
New regulation on medical devices made of substances: Opportunities and challenges for pharmacological and toxicological research 163
Antimicrobial-induced torsades de pointes: towards risk stratification by data mining of the FDA Adverse Event Reporting System. 162
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 162
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment 161
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies 159
Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials 159
Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies 159
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 157
Recurrence of pericarditis after influenza vaccination: a case report and review of the literature 156
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System 155
Use and Perception of Phytoestrogens in Postmenopausal Women: Result of a Questionnaire-Based Survey 154
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase 153
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations 152
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase 152
Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling 151
Macrolides and Torsadogenic Risk: Emerging Issues from the FDA Pharmacovigilance Database 151
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 151
The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. 149
Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective 148
The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia 148
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement 146
Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system 146
Infarto del miocardio, edema maculare e fratture associate ai glitazoni: analisi del database di segnalazione spontanea FDA_AERS 144
Apparato Gastroenterico 144
The beta3-adrenoceptor as a therapeutic target: current perspectives. 144
Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease 144
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety 144
Attitudes, barriers, and facilitators toward tools supporting appropriate prescribing among healthcare professionals: a cross-sectional study 143
Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. 142
Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: Insight from a pharmacovigilance study 141
Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. 140
Role of drugs and devices in patients at risk of sudden cardiac death. 140
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 140
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality 140
Association between the use of proton pump inhibitors and cardiovascular events: A note of caution 139
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration 138
Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System 138
Stroke, Migraine and Triptans: From Bedside to Bench 138
Impact of notoriety bias on reporting of pancreatitis with antidiabetics: the case of exenatide 136
The interface of depression and diabetes: treatment considerations 135
Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden. 134
Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews 134
Totale 18.999
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.716
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 321
Totale 86.037
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021906 0 0 0 0 0 0 0 0 0 104 135 667
2021/20222.983 301 89 140 125 239 184 182 242 154 147 642 538
2022/20233.487 382 404 265 413 246 231 167 257 517 171 276 158
2023/20241.432 91 178 166 235 118 181 62 110 43 94 86 68
2024/20255.077 285 692 551 289 616 271 339 216 156 342 298 1.022
2025/202611.399 1.134 1.151 1.173 877 1.303 685 1.798 476 2.020 782 0 0
Totale 30.271